These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

582 related items for PubMed ID: 31303349

  • 21. Association of renin-angiotensin system inhibitors with long-term outcomes in patients with systolic heart failure and moderate-to-severe kidney function impairment.
    Higuchi S, Kohsaka S, Shiraishi Y, Katsuki T, Nagatomo Y, Mizuno A, Sujino Y, Kohno T, Goda A, Yoshikawa T, West Tokyo Heart Failure (WET-HF) Registry Investigators.
    Eur J Intern Med; 2019 Apr; 62():58-66. PubMed ID: 30737061
    [Abstract] [Full Text] [Related]

  • 22. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Blais J, Li Q, Jardine MJ, Perkovic V, Wheeler DC.
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [Abstract] [Full Text] [Related]

  • 23. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
    Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C.
    Eur J Heart Fail; 2013 Nov; 15(11):1236-44. PubMed ID: 23787721
    [Abstract] [Full Text] [Related]

  • 24. Anemia as a risk factor for kidney function decline in individuals with heart failure.
    Bansal N, Tighiouart H, Weiner D, Griffith J, Vlagopoulos P, Salem D, Levin A, Sarnak MJ.
    Am J Cardiol; 2007 Apr 15; 99(8):1137-42. PubMed ID: 17437743
    [Abstract] [Full Text] [Related]

  • 25. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S, García CO, Rodríguez E, Barrios C, Otero S, Mojal S, Pascual J, Soler MJ.
    Nefrologia (Engl Ed); 2018 Apr 15; 38(2):197-206. PubMed ID: 29102270
    [Abstract] [Full Text] [Related]

  • 26. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators.
    Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, Ney DE, Makris L, Chang PI.
    J Am Coll Cardiol; 1997 Oct 15; 30(4):983-91. PubMed ID: 9316528
    [Abstract] [Full Text] [Related]

  • 27. Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction.
    Gregory DD, Sarnak MJ, Konstam MA, Pereira B, Salem D.
    Am J Cardiol; 2003 Dec 01; 92(11):1300-5. PubMed ID: 14636907
    [Abstract] [Full Text] [Related]

  • 28. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial.
    Ihle BU, Whitworth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ.
    Am J Kidney Dis; 1996 Apr 01; 27(4):489-95. PubMed ID: 8678058
    [Abstract] [Full Text] [Related]

  • 29. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA, Onuigbo NT.
    QJM; 2008 Jul 01; 101(7):519-27. PubMed ID: 18375475
    [Abstract] [Full Text] [Related]

  • 30. Association Between Midlife Obesity and Kidney Function Trajectories: The Atherosclerosis Risk in Communities (ARIC) Study.
    Yu Z, Grams ME, Ndumele CE, Wagenknecht L, Boerwinkle E, North KE, Rebholz CM, Giovannucci EL, Coresh J.
    Am J Kidney Dis; 2021 Mar 01; 77(3):376-385. PubMed ID: 32979415
    [Abstract] [Full Text] [Related]

  • 31. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 32. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA, OVERTURE Investigators.
    Am Heart J; 2005 Aug 20; 150(2):257-62. PubMed ID: 16086927
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJV.
    Circulation; 2021 Jan 26; 143(4):298-309. PubMed ID: 33040613
    [Abstract] [Full Text] [Related]

  • 34. Effects of Dietary Sodium Restriction in Kidney Transplant Recipients Treated With Renin-Angiotensin-Aldosterone System Blockade: A Randomized Clinical Trial.
    de Vries LV, Dobrowolski LC, van den Bosch JJ, Riphagen IJ, Krediet CT, Bemelman FJ, Bakker SJ, Navis G.
    Am J Kidney Dis; 2016 Jun 26; 67(6):936-44. PubMed ID: 26803690
    [Abstract] [Full Text] [Related]

  • 35. Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study.
    Hundemer GL, Knoll GA, Petrcich W, Hiremath S, Ruzicka M, Burns KD, Edwards C, Bugeja A, Rhodes E, Sood MM.
    Am J Kidney Dis; 2021 Feb 26; 77(2):178-189.e1. PubMed ID: 32920153
    [Abstract] [Full Text] [Related]

  • 36. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients.
    Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS.
    Kidney Int; 2000 Feb 26; 57(2):590-600. PubMed ID: 10652036
    [Abstract] [Full Text] [Related]

  • 37. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
    Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moyé LA, Pfeffer MA, Solomon SD.
    Circulation; 2004 Dec 14; 110(24):3667-73. PubMed ID: 15569840
    [Abstract] [Full Text] [Related]

  • 38. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.
    Nichols GA, Déruaz-Luyet A, Brodovicz KG, Kimes TM, Rosales AG, Hauske SJ.
    BMC Nephrol; 2020 May 07; 21(1):167. PubMed ID: 32380961
    [Abstract] [Full Text] [Related]

  • 39. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME.
    JAMA Intern Med; 2020 May 01; 180(5):718-726. PubMed ID: 32150237
    [Abstract] [Full Text] [Related]

  • 40. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
    Damman K, Solomon SD, Pfeffer MA, Swedberg K, Yusuf S, Young JB, Rouleau JL, Granger CB, McMurray JJ.
    Eur J Heart Fail; 2016 Dec 01; 18(12):1508-1517. PubMed ID: 27427441
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.